Skip to main content
OTCMKTS:PNEXF

Pharnext Stock Forecast, Price & News

$3.99
0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.99
▼
$3.99
50-Day Range
$3.99
▼
$4.12
52-Week Range
$3.56
▼
$4.29
VolumeN/A
Average Volume500 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PNEXF News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharnext and its competitors with MarketBeat's FREE daily newsletter.


Pharnext logo

About Pharnext

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.

Headlines

Pharnext (OTCMKTS:PNEXF) Shares Down 3.2%
Pharnext (OTCMKTS:PNEXF) Shares Down 3.2%
May 7, 2021 |  americanbankingnews.com
Pharnext SA reports FY results
Pharnext SA reports FY results
April 27, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PNEXF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.pharnext.com
Phone33 1 41 09 22 30
Employees44
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Medical Sector

1950th out of 2,044 stocks

Biotechnology Industry

138th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pharnext (OTCMKTS:PNEXF) Frequently Asked Questions

Is Pharnext a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharnext in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Pharnext stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PNEXF, but not buy additional shares or sell existing shares.
View analyst ratings for Pharnext or view top-rated stocks.

What stocks does MarketBeat like better than Pharnext?

Wall Street analysts have given Pharnext a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pharnext wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Pharnext's key executives?

Pharnext's management team includes the following people:
  • Mr. Daniel E. Cohen, Director (Age 68, Pay $375.76k)
  • Dr. David Horn Solomon, CEO & Director (Age 61)
  • Mr. Serguei Nabirotchkin, Co-Founder & Chief Biology Officer
  • Mr. Ilya Chumakov Ph.D., D-Sc, Co-Founder, Chairman of Scientific Advisory Board and Director
  • Mr. Peter J. Collum, CFO & Chief Bus. Officer
  • Mr. François Chamoun, Gen. Counsel
  • Mr. Xavier Paoli, VP & Chief Commercial Officer
  • Ms. Susanne Dorn, Chief Regulatory Officer
  • Mr. Rodolphe Hajj, Chief Pharmacology Officer
  • Ms. Viviane Bertrand, Chief Preclinical Drug Devel. Officer

Who are some of Pharnext's key competitors?

Some companies that are related to Pharnext include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of PNEXF's competitors.

What is Pharnext's stock symbol?

Pharnext trades on the OTCMKTS under the ticker symbol "PNEXF."

How do I buy shares of Pharnext?

Shares of PNEXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharnext's stock price today?

One share of PNEXF stock can currently be purchased for approximately $3.99.

How many employees does Pharnext have?

Pharnext employs 44 workers across the globe.

What is Pharnext's official website?

The official website for Pharnext is www.pharnext.com.

How can I contact Pharnext?

The company can be reached via phone at 33 1 41 09 22 30.


This page was last updated on 5/15/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.